Study Enrollment

Your details will not be published or shared.

Clinical Trial

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

This is a clinical trial for patients with cystic fibrosis that may allow them to breath easier and prevent lung infections.

Eligibility Criteria

  • Inclusion Criteria Subjects should be willing to sign an informed consent document and get finished with the parent study and be willing to stay on this study until their treatment is complete. Exclusion Criteria: 1. History of any other diseases, 2. Pregnant and nursing females.3. History of drug allergy in the parent study that would pose an additional risk to the subject in the opinion of the investigator. 4. Current participation in another research study using drugs

Contact Information

    Caralee Forseen MD

    (706) 721-2566